SPATS2L (spermatogenesis associated serine rich 2 like) is a cytosolic and nucleolar protein with RNA-binding capacity that functions as a positive feedback regulator of type I interferon signaling 1. The gene is highly expressed in disease contexts and serves as a prognostic biomarker across multiple malignancies. In acute myeloid leukemia (AML), high SPATS2L expression is an independent poor prognostic indicator and correlates with chemotherapy resistance 2. SPATS2L knockdown suppresses AML cell growth, induces apoptosis, and inhibits the JAK2/STAT3/STAT5 pathway, suggesting therapeutic potential 2. SPATS2L is also identified as a key prognostic gene in AML risk stratification 3 and serves as an immunohistochemical surrogate marker for BCR::ABL1-positive and BCR::ABL1-like B-acute lymphoblastic leukemia, with 83% sensitivity and 95% specificity 4. In systemic lupus erythematosus, SPATS2L acts as a susceptibility gene associated with disease activity through interferon pathway amplification 1. SPATS2L dysregulation also contributes to cisplatin resistance in laryngeal squamous cell carcinoma via the HOXA11-AS/miR-518a axis 5, and genetic variants affect bronchodilator response in asthma 6. Reduced SPATS2L expression from aberrant DNA methylation impairs trophoblast invasion in recurrent miscarriage 7. Collectively, SPATS2L represents a critical disease biomarker with therapeutic targeting potential.